Flagship Communities Real Estate Investment Trust Announces Largest Acquisition in the REIT’s History
April 17, 2024 16:27 ET
|
Flagship Communities Real Estate Investment Trust
EXPANDS FOOTPRINT INTO NASHVILLE, TENNESSEE ENTERS EIGHTH NEW U.S. STATE OF WEST VIRGINIA ANNOUNCES US$60 MILLION PUBLIC EQUITY OFFERING Not for distribution to U.S. newswire services or...
Global Corneal Implants Market Size To Worth USD 763.0 Million By 2033 | CAGR Of 5.9%
April 16, 2024 13:00 ET
|
SPHERICAL INSIGHTS LLP
New York, United States , April 16, 2024 (GLOBE NEWSWIRE) -- The Global Corneal Implants Market Size is to Grow from USD 429.9 Million in 2023 to USD 763.0 Million by 2033, at a Compound Annual...
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
April 15, 2024 07:00 ET
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through...
Sight Sciences gibt die Veröffentlichung einer groß angelegten, praxisnahen MIGS-Studie als Nachweis für die Wirksamkeit des umfassenden Verfahrens zur Wiederherstellung des Kammerwasserabflusses mit der OMNI® Surgical System-Technologie sowohl bei der Senkung des Augeninnendrucks als auch bei der Einnahme von Medikamenten zur Senkung des Augeninnendrucks über einen Zeitraum von 2 Jahren bei Patienten mit Glaukom bekannt
April 12, 2024 04:00 ET
|
Sight Sciences, Inc.
MENLO PARK, Kalifornien, April 12, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) („Sight Sciences“ oder das „Unternehmen“), ein Technologieunternehmen im Bereich der Augenheilkunde,...
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
April 10, 2024 16:05 ET
|
Sight Sciences, Inc.
MENLO PARK, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and...
Optometry Equipment Market is Expected to Reach $6.1 billion | MarketsandMarkets™
April 10, 2024 08:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, April 10, 2024 (GLOBE NEWSWIRE) -- Optometry Equipment market in terms of revenue was estimated to be worth $4.5 billion in 2024 and is poised to reach $6.1 billion by 2029, growing at a...
Precision Neuroscience Names Verily Co-Founder Brian Otis as Chief Technology Officer
April 08, 2024 11:53 ET
|
Precision Neuroscience
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision) today announced that Dr. Brian Otis has joined the company as Chief Technology Officer. An expert in chip...
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists
April 02, 2024 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
- Charles Wykoff, M.D., Ph.D. joins Carl Regillo, M.D., FACS as co-chair of Scientific Advisory Board –- Usha Chakravarthy, M.B.B.S, PhD., Allen Ho, M.D. FACS FASRS and Frank Holz, M.D., F.E.B.O,...
Lifecore Biomedical Provides Business Update Outlining Fiscal 2024 Outlook and Year-to-date Progress
April 01, 2024 08:00 ET
|
Lifecore Biomedical, Inc.
Year-to-date Results Consistent with Prior Expectations; Experiencing Fiscal Second Half Lift Provides Fiscal 2024 Full Year Guidance Commercial Momentum Continues within Development Portfolio ...
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 29, 2024 08:00 ET
|
KALA BIO, Inc.
-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 ---- Exploring opportunities to expand KPI-012 into additional corneal indications ---- Cash...